Yesterday, Johnson & Johnson COVID-19 vaccine supplier Janssen Biotech, Inc. released a statement regarding the potential risks of their adenovirus vaccine. The updated disclaimer states:
Read More »Recently, reports have been published associating adenovirus vector COVID-19 vaccines and the onset of unusual variants of Guillain-Barré syndrome (GBS). Notably, experts highlight that there have been no findings suggesting COVID vaccines cause GBS. However, the timing of the condition’s onset occurring shortly after vaccination has raised questions among researchers.
Read More »A trial funded by the NIH has entered Phase 1/2 testing to study COVID-19 vaccine boosters from different manufacturers on fully vaccinated adults. While it has not been determined whether boosters will be necessary, Dr. Fauci has stated that “we need to prepare for the possibility… to counter waning immunity and to keep pace with an evolving virus”
Read More »This past Friday, the CDC lifted the pause on Johnson & Johnson’s COVID-19 vaccine usage. During this pause, which was announced on April 13, the CDC confirmed an additional 9 cases of women developing thrombosis with thrombocytopenia syndrome (TTS) blood clots with low platelet count after receiving the J&J vaccine. The pause was initiated after 6 cases were presumed to be linked to the J&J vaccine. 13 of the 15 women were between the ages of 18-49.
Read More »